Transcription factors with helix-loop-helix (HLH) motif play critical roles in controlling the expression of genes involved in lineage commitment, cell fate determination, proliferation, and tumorigenesis. To examine whether the newly identified HLH protein GCIP/CCNDBP1 modulates cell fate determination and plays a role in hepatocyte growth, proliferation, and hepatocarcinogenesis, we generated transgenic mice with human GCIP gene driven by a liver-specific albumin promoter. We demonstrated that in GCIP transgenic mice, the overall liver growth and regeneration occurred normally after liver injury induced by carbon tetrachloride (CCl 4 ). In the diethylnitrosamine (DEN)-induced mouse hepatocarcinogenesis, we demonstrated that overexpression of GCIP in mouse liver suppressed DEN-induced hepatocarcinogenesis at an early stage of tumor development. The number of hepatic adenomas at 24 weeks was significantly lower or not detected in GCIP transgenic male mice compared to the control mice under the same treatment. Although GCIP has little inhibition on the number of hepatic tumors at later stages (40 weeks), hepatocellular tumors in GCIP transgenic mice are smaller and well-differentiated compared to the poorly differentiated tumors in wildtype mice. Furthermore, we demonstrate that GCIP functions as a transcriptional suppressor, regulates the expression of cyclin D1, and inhibits anchorage-independent cell growth and colony formation in HepG2 cells, suggesting a significant role of GCIP in tumor initiation and development.
Introduction
Liver cancer is the third most common causes for cancer death in the world. In 2005, a total of 15 420 estimated deaths by liver/intrahepatic bile duct cancer are expected in the US, including 10 330 male cases and 5090 female cases (Jemal et al., 2005) . Although lots of research has been performed to study the mechanism of hepatocarcinogenesis, few of them are related to the early stage of liver tumor development. Helix-loop-helix (HLH) proteins are key regulators of cell growth and differentiation in embryonic and adult tissues. They have been demonstrated to play critical roles in regulation of gene expression, cell cycle control, cell lineage commitment and numerous developmental processes (Blackwell et al., 1990; Kreider et al., 1992; Zebedee and Hara, 2001) . From the yeast to humans, over 240 HLH proteins have been identified to date (Massari and Murre, 2000) . Based upon the presence or absence of DNA-binding domain and other additional functional domains, HLH proteins can be classified into five major classes, basic HLH (bHLH) proteins, basic HLH Per-AhR-Arnt-Sim (bHLH-PAS) proteins, basic HLH leucine zipper (bHLH-LZ) proteins, dominant-negative HLH (dnHLH) proteins, and HLH leucine zipper (HLH-LZ) proteins. In multicellular organisms, bHLH proteins are required for many important developmental processes, including neurogenesis (Lee et al., 1995; Ma et al., 1996; Sun et al., 2001) , myogenesis (Nabeshima et al., 1993; Molkentin et al., 1995; Spicer et al., 1996) , hematopoiesis (Kreider et al., 1992; Zhao and Aplan, 1999; Barndt et al., 2000) , and pancreatic development (Jensen et al., 2000; Pin et al., 2001) . On the basis of tissue distribution and dimerization capabilities, bHLH protein can be further divided into two subgroups. One subgroup also known as the E proteins and includes E12, E47, E2-5, E2-2, HEB, and Daughterless. These proteins are ubiquitously expressed in many tissues and capable of forming either homo-or heterodimers (Zhuang et al., 1992; Shirakata and Paterson, 1995) . The DNA-binding specificity of E proteins is limited to the E-box site, which have the consensus sequence CANNTG (Cordle et al., 1991; Voronova and Lee, 1994) . The other subgroup bHLH proteins show a tissue-restricted pattern of expression and regulate tissue-specific cell growth and differentiation. Examples include the myogenic bHLH family of proteins (MyoD, Myogenin, MRF4) , the cardiogenic family of proteins (eHand and dHand), the neurogenic family of proteins (Neurogenin, NeuroD, Mash-1, Mash-2, Hes, NSCL), and the haemopoietic family of bHLH proteins (SCL/TAL-1, Lyl-1, and ABF-1) (Murre et al., 1989; Lassar et al., 1991; Hu et al., 1992; Kee et al., 2000) . With few exceptions, they are incapable of forming homodimers and preferentially heterodimerize with the E proteins. The heterodimers can bind both canonical (CANNTG) and noncanonical (CACNAG) E-box sites (Gaubatz et al., 1994) . Dominant-negative HLH proteins, including Id proteins (Id1, Id2, Id3, Id4) and emc, are small proteins lack a basic region. Owing to a lack of the basic region, the Id proteins appear to function as dominant-negative regulators of bHLH proteins through the formation of 'nonfunctional' Id/bHLH heterodimers, thus quench the activity of the E proteins, inhibit cell differentiation and regulate tumorigenesis (Benezra et al., 1990; Sun et al., 1991; Peppelenbosch et al., 1995; Yokota and Mori, 2002; Perk et al., 2005) . Mice deficient in the Id family of proteins have profound defects in neurogenesis, angiogenesis, vascularization of tumor xenografts, impaired immune responses, and tumorigenesis (Lyden et al., 1999; Rivera et al., 2000; Rivera and Murre, 2001; Ruzinova and Benezra, 2003; Sikder et al., 2003) .
GCIP (CCNDBP1) is a HLH leucine zipper (HLH-LZ) proteins without basic DNA-binding region, which was identified and characterized in our lab and others to interact with cyclinD1 (DIP1) and as a human homologue of MAID protein (HHM) (Hwang et al., 1997; Terai et al., 2000; Xia et al., 2000; Yao et al., 2000) . GCIP gene is localized on chromosome 15q15, a region frequently deleted or undergoes loss of heterozygosity (LOH) in different tumors, including colorectum, breast, lung, and bladder tumor (Natrajan et al., 2003) . Previous data demonstrate that GCIP is expressed specifically in foci of the 2-acetylaminofluorene/ partial hepatectomy (AAF/PH) model, which is used to monitor the differentiation of rat hepatic stem cells into hepatocytes, suggesting GCIP may be involved in the hepatic stem cell development and differentiation processes (Terai et al., 2000) . GCIP was also showed to regulate the transcription of hepatocyte nuclear factor 4 (HNF4), which has E-box sequences in its promoters, thus suggesting that GCIP might be involved in the liver growth and differentiation (Terai et al., 2000; Takami et al., 2005) . High-level expression of GCIP was found from the very early stages of hepatocarcinogenesis, suggesting that GCIP might be involved in hepatocarcinogenesis (Takami et al., 2005) .
In this study, we have generated GCIP transgenic mice in the liver and characterized the effects of GCIP in liver regeneration after injury and in hepatocarcinogenesis induced by diethylnitrosamine (DEN). Our data demonstrate that in GCIP transgenic mice, the overall liver growth, cell proliferation, and regeneration occurred normally compared to the wild-type mice after liver injury induced by carbon tetrachloride (CCl 4 ). In the mouse model of hepatocarcinogenesis induced by DEN, we observed that overexpression of GCIP in transgenic mice suppressed the number of chemicalinduced hepatocarcinogenesis at the early stage of tumor development. At the late stage, hepatocellular tumors in GCIP transgenic mice are smaller and welldifferentiated compared to the poorly differentiated tumors in wild-type mice. We further demonstrated that GCIP functions as a general transcriptional suppressor. Overexpression of GCIP inhibited anchorage-independent cell growth and colony formation whereas downregulation of GCIP promotes colony formation in HepG2 cells. These data suggest that GCIP may function as an important negative regulator in tumor initiation and progression but does not alter the proliferation of normal hepatocytes following liver injury. These findings suggest GCIP maybe an attractive target for prevention of hepatocellular carcinoma.
Results

Generation of transgenic mice overexpressing GCIP under the control of the albumin promoter
The full-length human GCIP was cloned from a human bone marrow cDNA library (clontech) (Xia et al., 2000) . Human GCIP cDNA fragment (1.1 kb) containing the entire coding region was inserted into the EcoRI site of an albumin promoter-driven expression vector ( Figure 1a ) and a chicken insulator is inserted at 3 0 -end of the transgene to ensure the expression of target gene. Two GCIP transgenic lines were developed and utilized for characterization. Transcription of human GCIP was identified by Northern blot analysis of liver mRNA using a 32 P-labeled human GCIP cDNA probe. Expected transcripts of the human GCIP transgene were found only in GCIP transgenic mice but not in control wild-type mice (Figure 1b) , whereas transcript of the mouse GCIP were found in both transgenic mice lines and control wild-type mice. The expression of GCIP mRNA in transgenic mice was approximately two to five folds higher than that of the endogenous murine GCIP gene. RT-PCR with primers specific to human GCIP also showed the presence of human GCIP mRNA in the liver of both Tg1 and Tg2 GCIP transgenic mice, with higher levels of expression in Tg1 GCIP transgenic animals, which is consistent with our results obtained from Northern blot analysis (Figure 1b and c) . Furthermore, we examined the expression of GCIP protein in transgenic mice using specific anti-GCIP antibody in Western blot analysis. As shown in Figure 1d , GCIP protein was at about two-to fourfold higher in transgenic mice than the endogenous mouse GCIP protein (Figure 1d ).
All GCIP transgenic mice appear to develop and reproduce normally. The GCIP transgenic mice showed no significant difference in liver weight relative to total body weight in comparison to age-matched controls in first 12 months (data not shown). Examination of multiple livers from Tg1 and Tg2 lines of transgenic GCIP mice and wild-type mice revealed no significantly difference in liver structure and hepatocyte morphology.
Normal liver regeneration and hepatocyte proliferation in GCIP transgenic mice after acute CCl 4 treatment The liver has a remarkable capacity to regenerate after injury. To determine the effect of GCIP overexpression on hepatocyte proliferation and regenerative capability, we induced liver injury and regeneration on 7-week-old male wild-type and GCIP transgenic mice by performing a single intraperitoneal injection of the liver toxin CCl 4 , which is known to cause hepatic injury by forming trichloromethyl free radical and altering the hepatocyte membrane permeability (Recknagel et al., 1989) . Histologically, GCIP transgenic mice and wild-type mice showed similar extent of hepatocellular injury at each time point (from 38 to 72 h) following acute CCl 4 exposure (Figure 2a) , demonstrating little or no difference in liver regeneration and heptocyte proliferation. Alanine transaminase (ALT), is used as a specific maker for hepatocyte injury (Wroblewski, 1959) . To determine the potential role of GCIP in hepatocyte injury and regeneration, we examined whether overexpression of GCIP affects ALT level in transgenic GCIP mice and in wild-type control mice. As shown in Figure 2b , in CCl 4 -induced liver injury, ALT levels increased and reached peak at 24 h in both wild-type and GCIP transgenic mice. There was no significant difference at ALT levels between wild-type and GCIP transgenic mice up to 72 h post-CCl 4 injection (Figure 2b ), indicating little effect of GCIP on the injury responses of the liver induced by CCl 4 injection.
To further examine whether overexpression of GCIP in transgenic mice affect cell proliferation during injury responses, we examined BrdU incorporation in the CCl 4 -injured liver and evaluated hepatocyte DNA synthesis and cell proliferation after CCl 4 injection. As shown in Figure 2c , both GCIP transgenic and wild-type mice showed similar patterns for BrdU incorporation with peak incorporation occurring at 48 h post-CCl 4 injection, suggesting GCIP has little effect on DNA synthesis and cell proliferation after CCl 4 injection in the transgenic liver. Together, these data support the idea that GCIP transgenic mice in the liver showed an unaltered liver damage and hepatocyte proliferation after acute CCl 4 treatment.
GCIP overexpression suppressed diethylnitrosamineinduced hepatocarcinogenesis in early stage of liver tumor development To elucidate the role of GCIP in hepatocarcinogenesis, DEN was administered to GCIP transgenic mice to induce liver tumorigenesis. As female mice are known to be resistant to hepatocarcinogenesis in experimental mouse models, including those employing chemical carcinogenesis, only male mice were used and analysed in our experiments (Diwan and Meier, 1976; Moore et al., 1981; Vesselinovitch, 1987; Lee et al., 1998; Nakatani et al., 2001) . In this commonly used neonatal DEN-induced hepatocarcinogenesis model, a single dose of 10 mg/kg DEN was intraperitoneally injected into 14-day-old wild-type and GCIP transgenic mice. The mice were killed 4, 6 or 10 months later. DEN-induced microfoci could be readily observed under light microscope in wild-type liver by 4 months. The most common foci were basophilic cell type, followed by clear cell type and the mixed type containing both types of cells. Hepatocyte dysplasia was apparent with increased nuclear/cytoplasm ratio, pleomorphism, vacuolization, and clear cell change. In general, while variations existed, there were no apparent differences in the histological changes between the wild-type and GCIP transgenic livers. However, there were significant differences in the number of foci and the size of foci between the GCIP transgenic mice and the wild-type mice. The number of hepatic adenomas at 24 weeks was significantly lower or not detected in GCIP transgenic male mice compared to the control mice under the same treatment by 24 weeks (Figure 3a-d) . Only 7.8% of GCIP transgenic males versus 38.5% of wild-type males developed liver adenomas by 24 weeks (Figure 3a-d ,  Table 1 ). However, after40 weeks, 85.7% of GCIP transgenic male mice developed liver tumors while 100% of the wild-type male mice developed liver tumor after DEN-treatment (Figure 3e -h, Table 1 ). The tumors in GCIP transgenic mice at 40 weeks are smaller and welldifferentiated (Figure 3g and h) compared to those found in wild-type mice (Figure 3e and f) . These data were consistent with the microfoci development at the early stage in the wild-types of mice and suggested that tumor development in the GCIP transgenic mice was delayed.
GCIP suppresses the tumorigenesis in HepG2 cells
To examine the effect of GCIP in tumorigenesis, we examined how GCIP regulated anchorage-independent cell growth through soft agar assays. HepG2 cells were stably transfected with pCMV-Tag2B control vector, pCMV-Tag2B-GCIP, and pU6-GCIPsiRNA plasmid, respectively. The transfected cells were analysed and compared in soft agar assays for tumorigenesis. As shown in Figure 4 , overexpression of GCIP inhibited HepG2 cell colony formation on soft agar (Figure 4a and b), whereas downregulation of GCIP by specific siRNA significantly increased the colony formation of HepG2 cells (Figure 4a and b) , suggesting that GCIP can function as a potential suppressor gene for anchorage-independent cell growth and colony formation.
GCIP functions as a transcriptional repressor through TSA/NaB insensitive pathways GCIP contains a putative HLH domain, an Asp/Glurich acidic domain, and a leucine-zip domain. The distinct domain structures suggest that GCIP could be a potential transcriptional regulator. To further determine the role of GCIP in general transcriptional regulation, we used L8G5-luc reporter, a luciferase reporter gene controlled by eight copies of the binding site for LexA immediately adjacent to five copies of the binding site for GAL4 (Figure 5a ). LexA-VP16 fusion coactivator was used as positive control to activated reporter to high levels of transcription (Figure 5a ). By fusing GCIP to the Gal4 DNA-binding domain, the Gal4-GCIP fusion protein was able to efficiently reduce the transactivation of L8G5-luc reporter activated by LexA-VP16. This Gal4-GCIPinduced inhibition was not affected when cells were incubated with either of the two HDAC inhibitors, trichostatin A (TSA) and sodium butyrate (NaB) (Figure 5a ). Both TSA and NaB are well-known HDAC inhibitors and were able to strongly promote transcriptional activation at indicated concentration. In the presence of TSA or NaB, cotransfection of Gal4-GCIP still strongly inhibited VP16-induced transcriptional activation in the L8G5-luciferase assays, suggesting that GCIP induced transcriptional inhibition is independent of the class I and class II HDACs, which are sensitive to the inhibition by TSA and NaB.
GCIP inhibits the expression of cyclin D1
To understand the potential mechanism of GCIP inhibition of cell proliferation and tumorigenesis, we examined how GCIP affects the expression of cyclin D1, a key molecule in cell proliferation and tumorigenesis. First, we investigated how GCIP regulates the transcriptional activation of cyclin D1 by transfecting HepG2 cells with the pCMV-Tag2B vector, pCMV-Tag2B-GCIP plasmid, or pU6-GCIPsiRNA plasmids, together with the À1745 cyclin D1 promoter-luciferase reporter. This cylcin D1 reporter is the orginal fragment of cyclin D1 5 0 sequence cloned from the PRAD1 break point (Motokura and Arnold, 1993) . Cell extract were assayed for luciferase or b-galactosidase activities 48 h later. As shown in Figure 5b , overexpression of GCIP can markedly inhibit cyclin D1 transcriptional activity while decreasing GCIP expression by specific siRNA in the cells can alleviate the inhibitory effect of cyclin D1 transcription (Figure 5b ). Based on the inhibitory effect of GCIP on the transcriptional activity of cyclin D1 promoter in the cell, we further examined whether GCIP could inhibit the expression of cyclin D1 protein in the cells. Cells were transfected with pCMV-Tag2B vector, pCMV-Tag2B-GCIP, or pU6-GCIPsiRNA, respectively. Total proteins were extracted and separated by SDS-PAGE. Western blot analysis was performed to examine the expression levels of the GCIP, cyclin D1, and actin. As shown in Figure 5c , GCIP protein was decreased in the cells transfected with pU6-GCIPsiRNA, confirming that pU6-GCIPsiRNA could efficiently decrease GCIP expression level (Figure 5c ). Down-regulation of GCIP greatly increased the expression level of cyclinD1 protein in the cells transfected with pU6-GCIPsiRNA while overexpression of GCIP decreased the expression of cyclin D1 in cells transfected with pCMV-Tag2B-GCIP (Figure 5c ), suggesting that GCIP is able to inhibit tumorigenesis by regulating the expression and function of cyclin D1 in the cell.
To further examine the in vivo effect of GCIP on cyclin D1 expression, RT-PCR analysis was performed to check the expression of cyclin D1 in liver of both 24 weeks and 40 weeks GCIP transgenic mice and wildtype mice that were treated with DEN. The results showed that lower levels of cylin D1 expression was present in 24 weeks' old GCIP transgenic mice compared with wild-type mice (Figure 5d ). However, there is little difference between the expression levels of cyclin D1 in 40 weeks old GCIP transgenic and wildtype mice (Figure 5d ), suggesting that cyclin D1 plays a key role in the effect of GCIP in tumor suppression.
Discussion
In the previous study, our group reported that GCIP was expressed highly in terminal differentiated tissues, including heart, muscle, peripheral blood leukocytes, and brain. Furthermore, in cells transfected with GCIP, phosphorylation of retinoblastoma (Rb) protein by cyclin D-dependent protein kinase was reduced and E2F1-mediated transcription activity was inhibited, suggesting GCIP could play a role in cell proliferation Cos-7 cells were transiently cotransfected with L8G5-luc reporter, LexA-VP16, Gal4-GCIP, or Gal4-vector control as indicated. Gal4-GCIP can efficiently suppress L8G5-luc transcription activated by LexA-VP16. TSA or NaB has little or no effect on the GCIP-induced transcriptional repression. (b) GCIP inhibits transcriptional activation of À1745 cyclin D1 promoter. HepG2 cells were plated and transiently transfected with pCMV-Tag2B vector, pCMV-Tag2B-GCIP plasmid, or pU6-GCIPsiRNA, together with the À1745 cyclin D1-luciferase reporter. Overexpression of GCIP significantly inhibited the transcriptional activity of cyclinD1 promoter while decreasing GCIP expression can upregulate cyclin D1 transcription. (c) Inhibition of cyclin D1 protein expression by GCIP. HepG2 cells were plated and transiently transfected with pCMV-Tag2B vector, pCMV-Tag2B-GCIP, and pU6-GCIPsiRNA plasmid, respectively. Cell extracts were assayed for the expression of GCIP, cyclin D1, and b-actin with specific antibodies using Western blot analysis 72 h later. Results showed that overexpression of GCIP markedly inhibited cyclinD1 expression while decreasing GCIP expression by siRNA significantly increased the expression of cyclin D1 protein in the cells. (d) RT-PCR with primers specific to the murine cyclin D1 were preformed to show the expression of cyclin D1 mRNA in liver of both 24 weeks and 40 weeks old GCIP transgenic mice and wild-type (WT) mice treated with DEN, with lower levels of cylin D1 expression in 24 weeks old GCIP transgenic mice. RT-PCR with GAPDH-specific primer was used as control. and differentiation (Xia et al., 2000) . Previous data from Thorgeirsson's group had shown that GCIP/HHM is expressed specifically in the foci of the 2-acetylaminofluorene/partial hepatectomy (AAF/PH) model and is likely to be involved in hepatic stem cell (hepatic oval cell) proliferation and differentiation (Terai et al., 2000) . GCIP/HHM was also demonstrated to regulate the transcriptional activation of hepatocyte nuclear factor 4 (HNF4) in reporter assays, suggesting a role of GCIP/ HHM in liver growth and differentiation (Terai et al., 2000) . Mouse GCIP, which is named as Maid (Maternal Id-like molecule), was isolated from a subtraction cDNA library enriched for maternal transcripts that are still present in the mouse 2 cell stage embryo (Hwang et al., 1997) . However, Maid is just one of the shorter splicing isoform of the mouse GCIP, the full-length mouse GCIP isoform has extra 47 amino acids at its amino terminus and shares an overall amino acid sequence identity of 79.2% homology with GCIP. Interesting, human GCIP also has multiple different splicing isoform. Totally 14 splice patterns (SP) from the Alternative Splicing Database (ASD) are shown for human GCIP. Five of them were valuated at high confidence level. Alternative splicing is an important mechanism to generate protein diversity and to determine the binding properties, intracellular localization, enzymatic activity, protein stability and posttranslational modifications of proteins in a tissue-specific or development-specific way (Sierralta and Mendoza, 2004; Cooper, 2005; Lee and Wang, 2005; Stamm et al., 2005) . Splice site mutations of tumor suppressor genes often create truncated proteins as classical nonsense mutations. Over the last two decades, many studies have reported cancer-specific alternative splicing in the absence of genomic mutations (Venables, 2004) . The ubiquitous expression of GCIP and multiple different splicing isoforms of GCIP suggest that GCIP may have multiple functions and involve in multiple different processes.
In this study, we have generated the GCIP transgenic mice by subcloning the human GCIP into a vector containing the albumin promoter to evaluate the in vivo function of GCIP in liver proliferation, differentiation, and tumorigenesis. No abnormal development was detected in GCIP transgenic mice both before and after birth. Cell proliferation during liver regeneration in response to CCl 4 induced liver injury was normal in GCIP transgenic mice compared with the wild-type mice. Although GCIP may affect E2F-1 and cyclinD1 activities in our in vitro assays, data obtained from the GCIP transgenic mice are similar to the overexpression of E2F-1 and cyclin D1 in mice liver (Conner et al., 2000; Ledda-Columbano et al., 2002) , in which no obvious changes was observed in hepatic regenerative growth and proliferation after partial hepatectomy (Conner et al., 2000) and mitogenic stimuli (LeddaColumbano et al., 2002) , respectively.
Liver regeneration following liver injury is known to depend on two processes. The first one is through hepatocyte division and usually happens after acute liver injury. If this process is impaired, liver repair depends on the recruitment of hepatic oval cells. Hepatic oval cells are able to proliferate and differentiate into hepatocytes. Oval cell proliferation is commonly seen in the preneoplastic stages of liver carcinogens and is believed to be the source of hepatocarcinogenesis after the exposure to hepatocarcinogens (Knight et al., 2000; Roskams et al., 2003; Theise et al., 2003; Lemmer et al., 2004) . GCIP is expressed specifically in the foci of the 2-acetylaminofluorene/partial hepatectomy (AAF/PH) model, indicating that it is more likely to be involved in hepatic oval cell proliferation and differentiation but not hepatocyte proliferation (Terai et al., 2000) . The involvement of GCIP in hepatic oval cell proliferation and differentiation may partly explain why there exists no difference in liver injury and hepatocyte proliferation between GCIP transgenic and wild-type mice after CCl 4 -treatment, while hepatic carcinogenesis after DEN-treatment was attenuated in the GCIP transgenic mice compared to wild-type mice.
It is known that early hepatocellular carcinoma (HCC) is usually a well-differentiated carcinoma and then gradually changes into a moderately differentiated and poorly differentiated phenotype during tumor progression (Sugihara et al., 1992) . GCIP expression was also detected in human liver tumor samples with immunostaining by specific anti GCIP antibody. GCIP protein was stained in 23 of 32 adenomatous hyperplasia (AH) samples (72%), 19 of 28 well-differentiated HCC samples (68%), and 9 of 18 poorly moderately differentiated HCC samples (50%). Expression of GCIP was high in the adenomatous hyperplasia (AH) and well-differentiated HCC samples but relatively low in the poorly differentiated HCC samples, suggesting that the decrease of GCIP might be a prerequisite event for further tumor progression (Takami et al., 2005) . In our present study, we demonstrated that overexpression of GCIP in mouse liver decreased susceptibility to DEN induced hepatocarcinogenesis in transgenic mice in the early stage of tumorigenesis. After given a single intraperitoneal injection of DEN, 38.5% of wild-type males developed liver tumors by 24 weeks, however, only 7.8% of transgenic males developed liver tumors at the same stage (Table 1) . These results raised the possibility that GCIP may have a tumor suppressor function in the early stage of the hepatocarcinogenesis. Although GCIP has little effect on the number of liver tumors in the later stage of tumor development (86% in GCIP transgenic mice versus 100% in WT mice), tumors in GCIP transgenic mice are smaller and well-differentiated compared to the tumors found in wild-type mice, suggesting an important inhibitory role of GCIP in liver tumor initiation and progression processes.
In our investigation of the potential mechanisms of GCIP in tumorigenesis and transcription regulation, we found that GCIP could function as a transcription repressor independent of the class I and class II HDAC proteins. The D-type cyclins (cyclins D1, D2, and D3) are key molecules in cell cycle progression, cell proliferation and tumorigenesis. The cyclin D proteins complex with cdk4 and cdk6 and thereby regulate transition from the G 1 phase into the S phase by phosphorylation and inactivation of the retinoblastoma protein (pRb) tumor suppressor. Amplification and/or overexpression of the cyclin D1 (bcl1, PRAD1, and CCND1) gene has been found in 11-13% of human hepatomas (Nishida et al., 1994 (Nishida et al., , 1997 Suzui et al., 2002) and other human cancers, such as in 30-40% of human breast cancers (Kenny et al., 1999; Pestell et al., 1999) . Overexpression of cyclin D1 is sufficient to initiate hepatocarcinogenesis in transgenic mice (Deane et al., 2001 (Deane et al., , 2004 . Thus, cyclin D1 can function as an oncogene in the liver and is a potential target for hepatoma prevention and therapy. Our finding that GCIP suppresses the liver tumorigenesis by significantly down-regulating the transcriptional activity and protein expression of cyclin D1 suggest a novel mechanism for GCIP as a potential tumor suppressor gene in human cancers. Future studies are underway in our laboratory to help us understand the function of GCIP as a tumor suppressor and a regulator in cell proliferation and differentiation processes.
Materials and methods
Generation of GCIP transgenic mice 1.1 kb human GCIP cDNA containing the entire coding region for the full-length human GCIP was inserted into the EcoRI site of an albumin promoter-driven expression vector (Figure 1a) . A chicken insulator is inserted at 3 0 -end of transgene to ensure the expression of target gene. This transgene was used to generate transgenic mice by injecting GCIP transgene into the pronucleus of FVB mice fertilized eggs, then eggs were transferred to the oviduct of pseudopregnant female FVB mouse. Transgenic mice were identified by Southern blot analysis of EcoRI digested tail genomic DNA using a 32 P-labeled 1.1 kb GCIP cDNA probe. To confirm Southern results, PCR analysis of mouse tail DNA was performed using oligonucleotide primers designed from the human GCIP gene. Transgenic mice and control mice used in this study were propagated by breeding with GCIP heterozygote transgenic males with wild-type FVB females. Mice were maintained in 12-h light/12-h dark cycles with free access to food and water. All animal studies were performed in accordance with the guidelines of the Institutional Animal Use and Care Committee of the Institute of Biosciences and Technology, Texas A&M University System Health Science Center.
GCIPsiRNA plasmid construction
For stable expression of GCIP siRNAs within cells, the U6 promoter was cloned in front of GCIP gene-specific targeting sequence (19 nt sequences GACTCAATGAGGCAGCTGT from GCIP cDNA separated by a 9 nt spacer from the reverse complement of the same sequence) and five thymidines (T5) as termination signal.
Experimental liver injury by administration of CCl 4 All mice were 7-week-old males and kept under 12-h light/12-h dark lighting cycles at 231C. Three to five 7-week-old male mice were used in each experimental group. A single dose of 2.0 ml/kg of body weight (2:5 v/v in mineral oil) was administered by intraperitoneal injection for CCl 4 -induced liver damage study. After the mice were weighed, anesthetized and exsanguinated, livers were excised for analysis.
ALT analyses
Blood was drawn from anesthetized mice through heart puncture and the serum was separated by centrifugation for 20 min. Blood plasma levels of ALT (aminotransferase) activity were immediately measured using the GP-Transaminase kit (No. 505-P, Sigma, St Louis, MO, USA) in per time point after CCl 4 injection.
Hepatocyte DNA synthesis assays Hepatocyte DNA synthesis was measured by bromodeoxyuridine (BrdU) incorporation. Mice were given intraperitoneally injections of 20 mg/ml BrdU (Boehringer, Mannheim, Indianapolis, IN, USA) in a dose of 50 mg/g body weight 2 h before killing. The liver samples were collected, fixed and paraffin-embedded at per time point after CCl 4 treatment as described in the text. Sections, 5-mm, were cut for immunohistochemistry (IHC). An ABC staining kit was purchased from Santa Cruz Biotechnology. Immunohistochemical staining follows the manufacturer's protocol from Santa Cruz Biotechnology, Santa Cruz, CA, USA. Briefly, anti-BrdU primary antibody (Sigma, no. 2531) was used at 1:500 in block serum. BrdU incorporation in fixed liver sections was visualized with an anti-BrdU monoclonal antibody and an alkaline phosphatase-conjugated secondary antibody. Positively staining hepatocytes nuclei and unstained cells were counted under a Nikon Digital camera Dxm1200 microscope, and BrdU incorporation was expressed as the percentage of the number of labeled hepatocytes in four or five visual fields per animal (magnification Â 100).
Diethylnitrosamine-induced liver tumor and histological procedures At 14 days of age, mice were given a single intraperitoneal injection of DEN (Sigma Chemical Co.) in a dose of 10 mg/kg of body weight. At 21 days of age, mice were separated by sex and their transgenicity was determined.
At 24 and 40 weeks of age, animals were killed and analysed. Representative sections from each lobe of the liver and visible tumors were fixed, sectioned, stained with hematoxylin and eosin (H&E), and examined for the presence of adenomas. Statistical analysis of tumor incidence was carried out using the Student's t-test.
Liver tissues were fixed overnight in Histochoice Tissue Fixative MB (no. H120-4L, Amresco, Solon, OH, USA), dehydrated through a series of ethanol treatments, and embedded in paraffin according to standard procedure. Sections were prepared and stained with H&E.
Northern blot analyses
Total RNA was isolated from liver using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA) and separated on 1% agarose-formaldehyde gel. RNA was transferred by capillary blotting overnight onto Hybond þ membrane (AmershamPharmacia Biotech, Piscataway, NJ, USA) in 10 Â SSC. GCIP probe was labeled with [a-32 P]dCTP (Amersham) using the Random Primers DNA Labeling system (Invitrogen), and hybridized according to the manufacturer's protocol. Prehybridization and hybridization were done in 10 ml Rapid Hyb buffer (Amersham) at 681C for 1 h and overnight, respectively. The blot was washed two times in 2 Â SSC with 0.1% SDS at room temperature for 30 min, followed by two washes in 0.1 Â SSC with 0.1% SDS at 681C for 30 min. We stripped the GCIP probe with 0.1% SDS and reprobed the blot with b-actin probe using the same protocol. Blots were exposed 3 h to overnight on BioRad Phosphorimager screen.
Cell culture and luciferase reporter assays The HepG2 cells were obtained from ATCC (Rockville, MD, USA) and maintained in a 371C incubator with 5% CO2 humidified air in Dulbecco's minimal modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum.
At 48 h after transfection of the plasmids, the cells in a 24-well plate were lysed and harvested in 200 ml reporter lysis buffer (Promega), and cell lysates were assayed for luciferase activities. The luciferase assay was carried out using luciferase assay kit (Promega) and Packard Topcount Scintillation Counter. Extracts were also assayed for b-galactosidase activity with the Galacto-Light Plust b-Galactosidase Reporter Gene Assay Systems system (Tropix). Each extract was assayed three times, and the mean relative light unit (RLU) was corrected by values obtained from an extract prepared from nontransfected cells. The relative luciferase activity was calculated as RLU/b-galactosidase.
Soft agar assay
Human liver HepG2 cells were cultured in DMEM containing 10% fetal calf serum and transfected by pCMV-Tag2B vector, the pCMV-Tag2B-GCIP plasmid, and the siRNA plasmidspecific for GCIP. Transfected cells will be selected with G418 for 7 days. After selection, cells will be analysed for colony growth by suspending in 0.3% agarose medium containing DMEM þ 5% FBS and layered onto a 2.5-ml bed of 0.6% agarose in a 35-mm dish with grids. Plates will be incubated 3 weeks, and the number of colonies >100 mm will be counted.
Statistical analysis
Difference between wild-type and GCIP-transgenic animals in the liver tumor incidence was examined for statistical significance using the t-test.
